financetom
Business
financetom
/
Business
/
M&T Offers Limited Positive Catalysts Ahead, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
M&T Offers Limited Positive Catalysts Ahead, Morgan Stanley Says
Sep 29, 2025 8:45 AM

11:17 AM EDT, 09/29/2025 (MT Newswires) -- M&T Bank ( MTB ) is offering limited positive catalysts in the near term amid lower rates, Morgan Stanley said in a note Monday.

"With rates coming down, we see fewer positive catalysts in the near-term," the report said. "We are moving to the sidelines in favor of other opportunities in our coverage."

The report said M&T has been successfully executing on its strategy to decrease criticized assets and release excess capital, backing higher dividends and buybacks.

The note also pointed to the bank as relatively neutral to interest rates, expecting less room for net interest margin expansion relative to other banks in the group.

"Incremental improvement on criticized loans from here will likely be less of a tailwind for the stock, now that criticized

loans are back at 1Q21 levels," the report said.

Morgan Stanley downgraded M&T to equal-weight from overweight while raising its price target to $251 from $236.

Price: 197.10, Change: -3.04, Percent Change: -1.52

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Apple Moving Forward With Tabletop Robot
Market Chatter: Apple Moving Forward With Tabletop Robot
Aug 14, 2024
02:23 PM EDT, 08/14/2024 (MT Newswires) -- Apple ( AAPL ) is pushing ahead with the development of a tabletop home device that features an iPad-like display and a robotic limb, Bloomberg reported Wednesday, citing people with knowledge of the matter. The tech giant has a team of several hundred people working on the product, which uses a robotic arm...
NeuroBo Pharmaceuticals Shares Rise After Reporting Q2 Results
NeuroBo Pharmaceuticals Shares Rise After Reporting Q2 Results
Aug 14, 2024
02:25 PM EDT, 08/14/2024 (MT Newswires) -- NeuroBo Pharmaceuticals ( NRBO ) shares were up nearly 8% in recent trading Wednesday after the company reported its Q2 results. The company reported Q2 net loss of $1.85 per diluted share, widening from a loss of $0.15 a year earlier. Three analysts surveyed by Capital IQ expected a loss of $1.12 The...
Gilead Sciences Insider Sold Shares Worth $406,150, According to a Recent SEC Filing
Gilead Sciences Insider Sold Shares Worth $406,150, According to a Recent SEC Filing
Aug 14, 2024
02:27 PM EDT, 08/14/2024 (MT Newswires) -- Johanna Mercier, Chief Commercial Officer, on August 13, 2024, sold 5,490 shares in Gilead Sciences ( GILD ) for $406,150. Following the Form 4 filing with the SEC, Mercier has control over a total of 114,979 shares of the company, with 114,979 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/882095/000112760224022176/xslF345X03/form4.xml Price: 74.01, Change: +0.02, Percent...
Arrowhead Pharmaceuticals to Advance Two Drug Candidates in Clinical Trials on Obesity
Arrowhead Pharmaceuticals to Advance Two Drug Candidates in Clinical Trials on Obesity
Aug 14, 2024
02:19 PM EDT, 08/14/2024 (MT Newswires) -- Arrowhead Pharmaceuticals ( ARWR ) plans to advance two advanced RNAi-based drug candidates, ARO-INHBE and ARO-ALK7, for clinical studies to target obesity and metabolic disorders. In preclinical tests, the drug candidates showed potential for reducing body weight and fat while preserving lean muscle mass better than existing therapies, Arrowhead said Wednesday The company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved